Ustekinumab (Stelara — Janssen Inc.) indication: psoriatic arthritis
CADTH
Record ID 32015000166
English
Authors' recommendations:
The Canadian Drug Expert Committee (CDEC) recommends that ustekinumab not be listed at the submitted price for the treatment of psoriatic arthritis.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/complete/cdr_complete_SR0359-000_stelara_october_22_2014.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antibodies, Monoclonal, Humanized
- Arthritis, Psoriatic
- Immunosuppressive Agents
- Treatment Outcome
- Tumor Necrosis Factor-alpha
- Methotrexate
- Antirheumatic Agents
- Drug Approval
- Psoriasis
- Canada
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.